Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | RHOC | P08134 | 3/20 | 0.60 |
| ▸ | RHOA | P61586 | 3/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | UBE2M | P61081 | 1/20 | 0.58 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.58 |
| ▸ | YAP1 | P46937 | 1/20 | 0.58 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14067044 | 0.87 | L3MBTL1 (0.67) | MGLLCYP3A4L3MBTL1RHOCRHOA | |
| SCHEMBL16332685 | 0.86 | YAP1 (0.71) | FAAHYAP1TEAD4PTPN1PTPN2 | |
| SCHEMBL315591 | 0.85 | MGLL (0.51) | MGLLCYP3A4L3MBTL1RHOCRHOA | |
| SCHEMBL20955957 | 0.85 | ALDH1A1 (0.66) | FAAHYAP1TEAD4PTPN1PTPN2 | |
| SCHEMBL1942746 | 0.84 | MEN1 (0.67) | MGLLCYP3A4UBE2MDCUN1D1YAP1 | |
| SCHEMBL9342656 | 0.84 | KMT2A (0.72) | MGLLCYP3A4L3MBTL1FAAHPTPN1 | |
| SCHEMBL23246064 | 0.81 | RHOC (0.60) | RHOCRHOAUBE2MDCUN1D1YAP1 | |
| SCHEMBL8283575 | 0.81 | PTPN2 (0.81) | MGLLCYP3A4L3MBTL1RHOCRHOA | |
| SCHEMBL23086080 | 0.81 | MGLL (1.00) | MGLLRHOCRHOAUBE2MDCUN1D1 | |
| SCHEMBL14626222 | 0.81 | L3MBTL1 (0.63) | MGLLCYP3A4L3MBTL1RHOCRHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | MGLL 2004/4885CYP3A4 143/4885L3MBTL1 3922/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | MGLL 4089/4885CYP3A4 824/4885L3MBTL1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.